Abstract: The present disclosure relates to a pharmaceutical composition comprising 177Lu-PSMA I&T and methods of administering the same. The administration of the composition results in a low absorbed radiation dose per gram of tissue in a human patient's body, including the kidneys, gastrointestinal tract, left colon, liver, rectum, red marrow, spleen, lacrimal glands, and salivary glands.

Abstract: The present disclosure relates to a radiopharmaceutical compositions, methods, and kits comprising 177Lu-PSMA I&T. The compositions, methods, and kits may have a molar ratio of the PSMA I&T to 177Lu from 4.4:1.0 to 7.6:1.0. The composition may be formulated as a solution for injection and the solution is suitable for administration at least 72 hours after formulation. The composition(s) have a radiochemical purity (RCP) of 95% or greater, 95.5% or greater, 96% or greater, 96.5% or greater, 97% or greater, 97.5% or greater, 98.0% or greater, 98.5% or greater, 99% or greater, or 99.5% or greater at administration.

Abstract: The present disclosure relates to a pharmaceutical composition comprising 177Lu-PSMA I&T and methods of administering the same. The administration of the composition results in a low absorbed radiation dose per gram of tissue in a human patient's body, including the kidneys, gastrointestinal tract, left colon, liver, rectum, red marrow, spleen, lacrimal glands, and salivary glands.

Abstract: The present disclosure generally relates to a radiopharmaceutical composition comprising 177Lu-PSMA I&T. The composition is formulated as a solution for injection and the solution is suitable for administration more than 72 hours after formulation. The composition may include ascorbic acid and have a pH of 3.5 to 4.5 in solution. In some examples, the composition is suitable for administration to a human patient in need thereof at least 90 hours after formulation, and the composition has a radiochemical purity of 95% or greater at administration.